I-Mab to Participate at the Truist Securities BioPharma Symposium

IMAB 10.28.2024

Full Press ReleaseSEC FilingsOur IMAB Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
  • 01.06.2025 - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference (In Person)

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]

ROCKVILLE, Md.,Oct. 28, 2024/PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium onNovember 7, 2024.

(PRNewsfoto/I-Mab Biopharma)

Event Details

Meeting Date

Thursday, November 7, 2024

Meetings

One-on-one and small group meetings: November 7, 2024

ManagementParticipants

Sean Fu, PhD, MBA, Interim Chief Executive Officer (CEO)

Joe Skelton, Chief Financial Officer (CFO)

Phillip Dennis, MD, PhD, Chief Medical Officer (CMO)

Tyler Ehler, Senior Director, Investor Relations

For more information, please contact yourTruist Securitiesrepresentative.

AboutI-Mab

I-Mab(NASDAQ: IMAB) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.I-Mabhas established operations inRockville, Maryland, andShort Hills, New Jersey. For more information, please visithttps://www.i-mabbiopharma.comand follow us onLinkedInandX.

For more information, please contact:

Tyler EhlerSenior Director, Investor RelationsIR@imabbio.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-truist-securities-biopharma-symposium-302287758.html

SOURCEI-Mab Biopharma

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com